OCUGEN, INC. Finance Lease, Right-of-Use Asset, before Accumulated Amortization
OCUGEN, INC. (OCGN) had Finance Lease, Right-of-Use Asset, before Accumulated Amortization of $0 as of 2021-12-31, per its 10-K filed 2022-02-28.
Discontinued › Notes › Leases
us-gaap:FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization · last filed 2022-02-28
- 2021-12-31: Finance Lease, Right-of-Use Asset, before Accumulated Amortization $0.00.
- 2021-09-30: Finance Lease, Right-of-Use Asset, before Accumulated Amortization $0.00.
- 2021-06-30: Finance Lease, Right-of-Use Asset, before Accumulated Amortization $0.00.
- 2020-12-31: Finance Lease, Right-of-Use Asset, before Accumulated Amortization $64.00K.
| Period end | Finance Lease, Right-of-Use Asset, before Accumulated Amortization |
|---|---|
| 2021-12-31 | $0.00 10-K · filed 2022-02-28 |
| 2021-09-30 | $0.00 10-Q · filed 2021-11-09 |
| 2021-06-30 | $0.00 10-Q · filed 2021-08-06 |
| 2020-12-31 | $64.00K 10-K · filed 2022-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cabaletta Bio, Inc. (CABA) | United States | $0.365B | -2.81 |
| Artiva Biotherapeutics, Inc. (ARTV) | United States | $0.367B | |
| FENNEC PHARMACEUTICALS INC. (FENC) | United States | $0.371B | -115.85 |
| C4 Therapeutics, Inc. (CCCC) | United States | $0.373B | -5.65 |
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |
| SAB Biotherapeutics, Inc. (SABS) | United States | $0.306B | -25.49 |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B |